Editas Medicine Prospects Evaluation
Trending News ☀️ Editas Medicine ($NASDAQ:EDIT) Inc. is a cutting-edge genomic editing company that is working on developing treatments for [...]
BofA Securities Initiates Editas Medicine with Neutral Rating
Trending News ☀️ BofA Securities has given Editas Medicine ($NASDAQ:EDIT) a neutral rating with an $18 price target. The company’s [...]
Editas Medicine Inc. is the best stock to invest in!
Trending News ☀️ Editas Medicine($NASDAQ:EDIT) Inc is a clinical-stage biotechnology company that focuses on developing transformative genomic medicines to treat [...]
Editas Medicine Announces Successful Engrafting of Patient in EDIT-301 Ruby Trial
Trending News ☀️ Editas Medicine($NASDAQ:EDIT) has announced the successful engrafting of a patient in the EDIT-301 Ruby trial for sickle [...]
Editas Medicine beats Q2 expectations on earnings and revenue
Trending News 🌥️ Editas Medicine ($NASDAQ:EDIT) posted a GAAP EPS of -$0.78, beating analysts’ estimates by $0.06. Revenue came in [...]
